Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
Ipamorelin, CJC-1295, tesamorelin, and semaglutide are popping up everywhere in sports medicine research. A new review in JBJS Rev just mapped out where the evidence actually stands for injectable peptides targeting recovery, tissue repair, and performance.
JBJS Rev
by Villegas Meza AD, Nocek M, Mitchell BC et al.
“Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. Villegas Meza AD(1), Nocek M(1), Mitchell BC(1)(2), Lizarraga M(3), DeFoor MT(1)(2), Ruzbarsky JJ(1)(2), Huard J(1), Philippon MJ(1)(2). Author information: (1)The Steadman Philippon Research Institute, Vail, Colorado. (2)The Steadman Clinic, Vail, Colorado. (3)University of California, San Francisco School of Medicine, San Francisco, California. BACKGROUND: Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus. PURPOSE: To summarize contemporary human and translational evidence (January 1, 2020-August 31, 2025) for injectable peptides relevant to orthopaedics and sports medicine, and to clarify safety, product quality, regulatory, antidoping implications, and clinical outcomes. STUDY DESIGN: Structured narrative review. METHODS: PubMed/MEDLINE, Embase, and Web of Science were searched (January 1, 2020-August 31, 2025). Eligible studies included randomized controlled trials, prospective human studies, and translational investigations directly applicable to musculoskeletal care; noninjectable formulations and nonmusculoskeletal indications were excluded. Results were synthesized qualitatively; risk of bias for human trials was appraised using standard tools. RESULTS: Five functional peptide classes were identified. Glucagon-like peptide-1 receptor agonists (e.g., semaglutide) are the only class supported by reproducible randomized evidence of symptomatic improvement in knee osteoarthritis, with benefits primarily mediated by clinically meaningful weight loss and putative anti-inflammatory effects, whereas structural cartilage modification remains unproven. Collagen-derived injectable preparations show preliminary postoperative symptom/early recovery benefits in small, single-center prospective human studies. Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions. CONCLUSIONS: Injectable peptides for sports medicine remain largely experimental. Clinical use should be confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols. Clinicians caring for athletes must counsel patients regarding uncertain efficacy, product quality, safety risks, and antidoping implications. LEVEL OF EVIDENCE: Level V. See Instructions for Authors for a complete description of levels of evidence. STRENGTH OF RECOMMENDATION TAXONOMY: Predominantly C. Copyright © 2026 by The Journal of Bone and Joint Surgery, Incorporated. Conflict of interest statement: Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSREV/B330).”
Here’s the real story: out of all the major peptide classes, only semaglutide—known for its GLP-1 receptor agonist action—has solid randomized human trial data for musculoskeletal benefits. Specifically, semaglutide delivered improvements for knee osteoarthritis, largely through weight loss and possible anti-inflammatory effects. If you’re hoping for cartilage regrowth, though, that’s still just a theory.
Collagen-derived injectables showed some promise in small studies for speeding up post-op recovery. These are early days: single-center trials, not big multicenter slam dunks.
Now the main event for most peptide researchers—regenerative peptides like BPC-157, thymosin derivatives, and growth hormone secretagogues such as ipamorelin, CJC-1295, and tesamorelin—are still in the “experimental” column. Human safety data is limited, and product quality can be hit or miss. Plus, anti-doping rules are a huge factor if you’re thinking about research with athletes.
Key takeaways for researchers:
Semaglutide has the best human evidence for knee OA, mostly via weight loss.
Collagen-based peptides might help after surgery—too soon for big claims.
GH secretagogues and regenerative peptides (think ipamorelin, CJC-1295, tesamorelin) need more clinical work.
Product quality and regulatory clarity are a work in progress. Check with your vendor before starting any new project.
If you’re in the peptide game, the field is wide open for well-designed studies and better sourcing. The next breakthrough could come from any lab with the right focus.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.